INTRODUCTION
A recent New York Times article revealed that a prominent Yale geneticist, in the spirit of collaboration, recently provided vast quantities of genetic data to researchers at China's Institute of Forensic Studies.Footnote 1 Unbeknownst to him, those data were ultimately used as part of a surveillance operation against China's Uighurs, a Muslim minority in the Xinjiang Province.Footnote 2 While legal and bioethical questions related to privacy and consent in clinical research appear to be well-settled problems of the past, more recent advances in genetic sequencing have renewed the challenge of balancing social benefits with individual legal rights. The implications of unsettled policy and regulatory structures in this area have far reaching consequences in a medical field that has prioritized large-scale, international collaboration.
Nevertheless, the advancement of genetic research and information technology has only intensified the demand for biobanks, biorepositories for human tissue samples,Footnote 3 and “[t]he move to global data sharing has been facilitated by funding bodies on both sides of the Atlantic.”Footnote 4 The aggregation and broad sharing of genetic data is revolutionizing modern medicine, but the foundation required to facilitate this development raises ethical and legal questions about the feasibility of obtaining meaningful consent in a rapidly developing field, participants' privacy, and the challenges of finding appropriate international meta-governance solutions.Footnote 5
In the U.S., it is taken for granted that the privacy interests in a participant's medical data are protected by the Health Insurance Portability and Accountability Act of 1996 (“HIPAA”),Footnote 6 informed consent practices, and other legislative guidance in placeFootnote 7 to protect human subjects taking part in clinical trials and research. Most U.S. health care providers are careful to comply with the informed consent and other requirements of HIPAA. However, groundbreaking developments in genetic and genomic research in the last twenty years have ignited the field of clinical genetic medicine and genetic research.Footnote 8 Both are predicated on the existence of large pools of genetic data, taken from broadly informed and consenting participants, and stored indefinitely for unspecified future use.Footnote 9 With the costs of genome sequencing rapidly decreasing,Footnote 10 and the promise of genomic medicine to treat and prevent genetic problems, or even prevent pre-symptomatic diseases, there is no shortage of willing participants.Footnote 11 Genetic data are, however, unique from other types of medical information stored and used for future research. While genetic data are technically ‘de-identified,’Footnote 12 genome sequences are specific to each individual (with the exception of identical twins), and recent studies have proven that even in large pools of de-identified genetic data, anonymity cannot be preserved, challenging our concepts of privacy.Footnote 13
There has been a massive shift towards higher efficiency and effectiveness in clinical research and personalized health care, which can be largely attributed to the rise in genomic medicine.Footnote 14 The current legal and regulatory framework, however, does not provide individuals with a meaningful consent process, or protection for individual privacy rights. Models being developed in other countries, however, as well as growing support for an alternative consent model, provide encouraging examples for the US, indicating that individual privacy rights need not be sacrificed for the greater medical benefit.
This article will explore these issues in six parts. Part I will provide readers an introduction to basic genetics, biobanking, and the individual and aggregate benefits of precision medicine. Part II will identify some of the privacy concerns and paradoxes raised by the current consent model and precision medicine. Part III assesses the current statutory and regulatory structures in place to protect individual's privacy rights in the U.S. Part IV discusses the implications of consent in an international arena. Part V discusses new and promising approaches used in other countries. Finally, Part VI makes policy recommendations for the US moving forward.
I. WHAT IS BIOBANKING?
A. Genetics, briefly…
First identified by Gregor Mendel in 1866, genes are the fundamental unit of heredity, and give us the ability to predictably determine the traits and characteristics of an organism.Footnote 15 Genes are made of deoxyribonucleic acid (“DNA”),Footnote 16 and a genome is an organism's complete set of DNA.Footnote 17 Human beings have three billion bases of DNA.Footnote 18 For most of its relatively brief existence, genetics research has been limited by both the complexity of the human genome and the available technology.Footnote 19
One massive, global project, however, changed the way scientists study the human body, health, and disease. After thirteen years of work, on April 14, 2003, the National Human Genome Research Institute (“NHGRI”),Footnote 20 the Department of Energy, and international contributors announced the completion of the Human Genome Project (“HGP”).Footnote 21 Initially proposed in 1985,Footnote 22 the first completely mapped human genome gave researchers “the blueprint for building a person,”Footnote 23 leading to a cascade of research and major impacts in the fields of clinical medicine, biotechnology, and pharmacology. Perhaps in part due to the ethical, legal, and social concerns raised by the HGP, Congress passed HIPAA relatively quickly when the HGP was halfway completed.Footnote 24 But the same action was not taken internationally.Footnote 25
Additionally, the HGP marked a new way of doing genetics research, functioning and thriving on principles of open access and sharing, and shifting genetics research from a “cottage industry approach based on bespoke laboratories, to high-throughput sequencing involving teams of multidisciplinary experts.”Footnote 26 Genome sequence data was available immediately, and free to the public.Footnote 27 Providing the complete genome for free resulted in some significant immediate ethical challenges regarding patenting and ownership of genetic information.Footnote 28 Nevertheless, current technology has benefitted from, and further entrenched, the foundational approach to open and international genetic data sharing practices of the HGP.Footnote 29 In the words of the NHGRI, “the era of team-oriented research in biology is here.”Footnote 30
In the last 20 years or so, increasing efficiency in the technology used to sequence a human genomeFootnote 31 has driven down the costs for the sequencing process.Footnote 32 In sequencing a single genome, the HGP came in under budget at $2.7 billion.Footnote 33 The cost has now dropped below $1000.Footnote 34 The increasing efficiency, efficacy, and decreasing cost of sequencing have skyrocketed demand in clinical and research settings. In North America alone, the precision medicine market “is projected to expand at a compound annual growth rate (“CAGR”) of 11.04%, leading to a revenue of USD $36.25 billion by 2023.”Footnote 35 In the next several years, genetic sequencing is anticipated to become a part of the regular primary care physician experience.Footnote 36 By 2025, scientists predict over one billion people will have had their genomes sequenced.Footnote 37 However, apprehensive public perception and concerns about data privacy and consent regarding storage and nonconsensual use remain significant unresolved issues.Footnote 38
B. What is Precision Medicine?Footnote 39
Nicholas Volker was born in 2005, just a few years after the completion of the HGP.Footnote 40 For two years, he was happy, healthy, and normal.Footnote 41 Shortly before his third birthday, Nic's health declined rapidly, and over the next four years he had over 100 operations,Footnote 42 and scores of other invasive and experimental treatments to keep him alive,Footnote 43 while doctors tried to figure out the cause and the cure. In 2009, Nic's genome was sequenced, and doctors were quickly able to detect a one-in-a-billion genetic mutation, which led to life-saving treatment.Footnote 44 Nic has been called “The First Child Saved by DNA Sequencing.”Footnote 45
This was the original promise of precision medicine – testing, diagnosis, and treatment without a diagnostic odyssey.Footnote 46 When DNA sequencing first entered the market, precision medicine appealed mainly for the diagnosis of disease in individuals who suffer from rare diseases, or diseases where treatment options are onerous and uncertain.Footnote 47 Now, precision medicine is increasingly being implemented in primary care settings,Footnote 48 and the information from an individual's genetic makeup is used to tailor both treatment and prevention strategies based on the individual's genetic makeup, environment, and lifestyle.Footnote 49 According to Dr. Megan Mahoney, chief of general primary care in the Department of Medicine's Division of Primary Care at Stanford University, “[p]recision medicine, as we hear about it, is more focused on crafting a tailored treatment once a diagnosis is made. What is interesting to me right now is less about how to tailor sophisticated treatment to specific diseases and more about upstream strategies to prevent disease worsening … [f]ocusing on prevention is where the country needs to go right now in order to rectify the healthcare crisis we are facing now.”Footnote 50
C. Health Benefits of Biobanking
While sequencing an individual's genome can be beneficial to that person, society also benefits from the aggregation and analysis of large volumes of genetic data.Footnote 51 These large pools of genetic data, which fall under the broad term “biobank,”Footnote 52 contribute “the complexity, diversity, and rich context … [which] provide the bases for novel insights into diseases that can be translated into personalized treatments.”Footnote 53 Additionally, aggregate genetic data provides information used in pharmacogenetics and stratified healthcare, and can provide a wealth of information that will most likely contribute to the development of more effective treatments and pharmaceuticals.Footnote 54 The aggregation and utilization of genetic data are likely to provide great economic benefit, both in terms of efficiency and marketable pharmaceutical options.
Biobanks are essential to the utility of genetic data and the future of precision medicine, both for the individual and in the aggregate.Footnote 55 And, the bigger the better. In the last decade, genetic biobanks have “increased in variety and capacity from small collections of samples to large-scale national or international repositories.”Footnote 56 To build these indispensable biobanks, it is critical that patients consent to share their data.Footnote 57 However, “[i]f on one hand, data sharing offers unprecedented opportunities in the field of precision medicine, on the other hand, it raises ethical, social, legal, and technological issues.”Footnote 58 It is fairly simple to acquire an individual's consent for individual use, but securing consent from individuals for indefinite storage and future, unspecified uses is more challenging. Individuals are suspicious of the big data black box, particularly when it pertains to highly personal, health related data.Footnote 59 In one study, over a third of the participants agreed that having their genetic information stolen would be as bad as having their financial identity stolen.Footnote 60 Furthermore, a recent study showed that even highly coded genetic data cannot preserve anonymity in storage or in use.Footnote 61 In the absence of anonymity and confidentiality, individuals want information regarding proposed uses, some type of decisional interest, and assurances of protection for their data.Footnote 62
Nevertheless, the benefits gained from research enabled by biobanking genetic data are already changing medicinal practice. In addition to the treatment possibilities available to individuals suffering from rare diseases, the preventive and diagnostic capabilities of precision medicine are expanding. Formerly, a clinician or researcher may have only been able to scan for a specific locus on a chromosome, now that clinician or researcher is able to conduct fairly detailed genome-wide scans.Footnote 63
For the individual participant, the prospect of genome sequencing within a primary care context will enable providers to make targeted recommendations for behavior change and future treatment decisions.Footnote 64 The information would also educate families as to their carrier status for specific mutations and other genetic concerns.Footnote 65 Current medicine is largely reactive, and “waits until a person is sick and then treats a disease, with varying levels of success.”Footnote 66 With precision medicine, participants will benefit from primary care that is predictive, preventive, personalized, and participatory.Footnote 67
But the health benefits to individuals are only a portion of the benefit of genome sequencing. The aggregate data in biobanks increase “opportunities for secondary widespread and ongoing use by diverse investigators,”Footnote 68 and are already transforming research into enigmatic diseases like cancer and Alzheimer's, as well as pharmaceutical developmentFootnote 69 and pharmacogenomics.Footnote 70 To that end, biobanks are expanding.Footnote 71
D. Economic Benefits of Biobanking
The benefits of biobanking genetic data are also economic. In his second inaugural address in 2013, President Barack Obama noted that “[e]very dollar we invested to map the human genome returned $140 to our economy.”Footnote 72 A few months later, Battelle released a report detailing the impacts of genomics on the U.S. economy.Footnote 73 The report, which stated that the human genome was as critical to biology as the periodic table is to chemistry, found that human genome sequencing projects “help[ed] generate nearly $1 trillion in economic output” in addition to the transformational changes in medicine.Footnote 74 In 2012 alone, genome sequencing and related businesses “drove $65 billion in economic output, created $19 billion in personal income, and supported, directly and indirectly, 152,000 jobs – again, just in the United States.”Footnote 75 Additionally, the report lauded the growth of genetics and genomic science as a true public-private partnership, with significant economic development contributing to private financial gain and $54.8 billion in tax revenue from the genomics sector and related businesses.Footnote 76 To take advantage of both the health and economic benefits, President Obama started the Precision Medicine Initiative, with the mission to “enable a new era of medicine through research, technology, and policies that empower patients, researchers, and providers to work together toward development of individualized care.”Footnote 77 While precision medicine and biobanks have already become an important part of our healthcare economy, individuals' wariness and confidentiality concerns may instead create a drag on demand. Genetic data sharing cannot happen without addressing individuals' privacy concerns.
II. PRIVACY CONCERNS AND PARADOX
Privacy may not be an absolute right in the United States, but “the protection of individual privacy is enshrined in legal instruments of all liberal democracies and is a benchmark of civil society.”Footnote 78 In their seminal article, The Right to Privacy, Justices Warren and Brandeis redefined the scope of protections under the property rights umbrella to include the right to be left alone, and said that “the right to liberty secures the exercise of extensive civil privileges … tangible, as well as intangible.”Footnote 79 Although not officially recognized by the Supreme Court as a Constitutional or fundamental right, a right to privacy has more recently been construed as a liberty interest, protected under common law by the Fifth and Fourteen Amendments to the U.S. Constitution from unwarranted government intrusion.Footnote 80 Privacy is commonly divided into three broad categories: physical privacy, informational privacy, and decisional privacy, the latter two of which are directly related to privacy interests in genetic data.Footnote 81
A. Informational Privacy Interest in Genetic Data
Informational privacy is commonly defined as an individual's interest in how information about them is collected, stored, and disseminated, and is closely tied to data privacy and data protection.Footnote 82 With the advent of the Information Age, challenges to informational privacy are becoming more prevalent. Nine of the ten largest U.S. government data breaches of all time occurred between 2009-2019.Footnote 83 Heightened risks are associated with the collection, storage, and dissemination of genetic material because it is uniquely personal and cannot be made anonymous.Footnote 84 Individual research participants' biobanked genetic data can reveal disease status, future likelihood or past presence of certain traits, relatedness within a cohort, and other private information.Footnote 85 In Whalen v. Roe, the Supreme Court's seminal informational privacy case, the Court pointed out that the “right to collect and use [individual's private] data for public purposes is typically accompanied by a concomitant statutory or regulatory duty to avoid unwarranted disclosures.”Footnote 86 As we move towards a precision medicine model, it will be critical to protect these interests with effective regulation and a meaningful consent process.
So, with more than 120 biobanks worldwide, and consent requirements even for individuals uncertain, who will be the gatekeeper? The nature of genetic data is also such that even small amounts or specific pieces of data can expose information about close relatives.Footnote 87 Recently, the question was raised when an identical twin decided to sequence her genome as part of a precision medicine, clinical sequencing initiative.Footnote 88 As twins, both individuals shared virtually all three billion base pairs that constitute their whole genome.Footnote 89 Motivated by the prospect of discovering whether she carries a specific cancer mutation, one twin engaged in clinical genomic sequencing research.Footnote 90 Her primary care doctor walked her through the informed consent protocol: “Are you aware that the test results may reveal information about yourself that you would rather not know, such as predispositions for diseases that might not be curable? Are you aware that you could be subject to genetic discrimination for life insurance or long-term disability insurance? Are you aware that if the security system is breached that the electronic delivery of your results could be accessed by someone else?”Footnote 91 She gave her consent.Footnote 92 While receiving the test was only contingent on her consent in the study, it made her own genetic data, and by proxy her twin sister's, available for research purposes – against her sister's wishes.Footnote 93
In Iceland, a country where nearly 40% of the population has contributed genetic information to extensive public-private biobanks, legal and ethical questions regarding familial consent are already at the forefront.Footnote 94 In 1998, Iceland's parliament passed the Health Sector Database Act, “which authorized the creation and operation of a centralized database of non-personally identifiable health data for use in producing new or improved methods of achieving better health, prediction, diagnosis and treatment of disease.”Footnote 95 Linking the encrypted genetic samples and information to accurate medical records and genealogical information efficiently yields beneficial results. So, on an opt-out basis, the Health Sector Database Act provides for this too.Footnote 96 In 2000, Ragnhildur Guðmundsdóttir requested that her deceased father's medical, genealogical, and genetic information be excluded from the database, claiming that she had a personal interest in excluding his information because of potential inference about her health.Footnote 97 Ultimately, the case made its way to the Icelandic Supreme Court, which held in favor of Ms. Guðmundsdóttir, for reasons of personal privacy.Footnote 98 In so holding, the Icelandic Supreme Court “appear[ed] to be the first to recognize that someone other than the source of genetic information […] has a legally cognizable privacy interest in the proband's information.”Footnote 99
In the time since that holding, Iceland and the rest of the world have begun to wrestle with the subsequent question – how far does the duty to warn extend for genomic data? When either researchers or health care providers are in possession of critical health information for individuals, complicated questions are implicated: “[A]t what age should they be told, and with what caveats? Should researchers only tell individuals about diseases that can be prevented — such as with a mastectomy — as opposed to those they can't stop, such as Alzheimer's? And what if people don't want to know?”Footnote 100 In Iceland, “regulators have repeatedly refused to let deCODE, Iceland's largest database, de-encrypt the data to identify these carriers, and notify them.”Footnote 101
B. Decisional Privacy for Unspecified uses
The storage and subsequent unspecified uses of genetic data for research purposes also implicates decisional privacy. Decisional privacy is “the exclusion of others from decisions, such as health care decisions … made by the person.”Footnote 102
Storage presents an issue as to who owns the data, who has access to the data, and who determines how the data will be used. As to the ownership of genetic data, if an individual sequences their genome for a precision health initiative, is ownership of those data being surrendered for any other uses? If so, what type of consent is legally appropriate in that situation? And what if the data are collected for a routine use or screening? The collection and storage of genetic material for newborn screening without consent has led to significant questions about ownership, storage, and use.Footnote 103 A recent case in Michigan illustrates that the issue has continued vitality.Footnote 104
Unspecified downstream use of genetic data also implicates decisional privacy questions. In a survey of patients from academic medical centers, “72% of respondents felt that it was important for them to be informed about research using samples that were anonymized … and 81% felt it was important to be informed of research using samples that were coded, or identifiable.”Footnote 105 However, the 2017 revisions to the “Common Rule” specifically endorsed broad consent.Footnote 106 Traditional informed consent requires the subject to participate “voluntarily and with sufficient information about the research activity to make a comprehending decision about participation,”Footnote 107 but genetic data may be collected for a primary research study, and stored for later uses.Footnote 108 Common features of genetic and genomic research, including indefinite storage and use of material, unspecified future use, broad sharing of data, limited control of downstream use, and limited right to withdraw, all challenge the informed consent model, as well as the individual's ongoing decisional privacy over one's own highly personal genetic data.Footnote 109 Furthermore, particularly when it comes to broad sharing and downstream use, “strict adherence to traditional consent standards may threaten the viability of many otherwise beneficial studies,” due to the cost and delay of requiring consent for each study or each use of a participant's genetic data.Footnote 110
Broad consent remedies the issue of the impracticability of informed consent for scientists, doctors, and researchers involved in genetic and genomic medicine and studies, but does not fix the issues of consent and decisional privacy for those participating.Footnote 111 When a study only obtains broad consent, a participant “cannot be informed of the specific risks and benefits of the research because the biobanks do not know what those risks or benefits may be; they do not even know what the research topics will be.”Footnote 112 And while broad consent is now widely allowed for admitting genetic data into a biobank, it challenges many of the privacy and autonomy concerns that led to the initial consent requirement.Footnote 113 Additionally, broad consent inherently authorizes permission for broad sharing for unspecified future use, which naturally results in an individual participant's lack of involvement and decisional privacy over such participants' own health data.Footnote 114 This creates the possibility of an individual's data being used for something objectionable to them. Think of the Xinjiang Province.Footnote 115
III. PRIVACY PROTECTIONS FOR HUMAN SUBJECTS RESEARCH UNDER CURRENT US LAW
A. Legislation Protecting Genetic Information
Current federal legislation provides some privacy protections for genomic data.Footnote 116 As previously noted, HIPAA is a privacy rule enacted during the HGP, in part to create a set of national standards for the protection of certain individual health information, called Protected Health Information (“PHI”).Footnote 117 HIPAA applies to “covered entities,” including health care providers in both clinical and research settings.Footnote 118 It also applies to business associates of health care providers and other covered entities.Footnote 119 Without an individual's permission, health care providers are permitted to disclose limited data sets for the purposes of research, public health, or health care operations.Footnote 120
PHI may include: the individual's past, present or future physical or mental health or condition, the provision of health care to the individual, or the past, present, or future payment for the provision of health care to the individual.Footnote 121 Data can be de-identified by a formal determination by a statistician or by the removal of specific identifiers of the individual, including biometric identifiers.Footnote 122 However, because of the nature of genetic material, it is difficult, if not impossible to effectively de-identify.Footnote 123 HIPAA does not restrict the use or disclosure of de-identified data.Footnote 124 In 2013, the HIPAA Omnibus Rule amended the regulations to include genetic information in the definition of PHI.Footnote 125 The classification, however, is tenuous. Genetic data are considered PHI, but the genetic sequence is not.Footnote 126 Therefore, “the minute the sequence is interpreted it becomes PHI.”Footnote 127
In 2008, Congress passed the Genetic Information Nondiscrimination Act (“GINA”) to prevent genetic information from being used for discriminatory purposes in health care, insurance, and employment.Footnote 128 While GINA is predominately anti-discrimination legislation, the Office for Human Research Protections (“OHRP”), an office in the U.S. Department of Health and Human Services (“DHHS”), issued guidance for how to incorporate GINA into clinical research and informed consent for participants in genomic research,Footnote 129 including a description of reasonably foreseeable risks to the participant, and “a statement describing the extent, if any, to which confidentiality of records identifying the subject will be maintained.”Footnote 130
In the United States, individual states are also passing legislation to address citizen's concerns over genetic privacy. Alaska, Colorado, Florida, Georgia, and Louisiana have all codified a property interest in genetic data and impose civil liability for violations.Footnote 131 The Alaska statute provides the broadest protection, giving individuals the exclusive right to their genetic data, as well as the sample, and requiring informed consent for storage and disclosure.Footnote 132 The scope of many state statutes does not go beyond the existing federal framework for protection of genetic data.Footnote 133
Protection under the Illinois Genetic Information Privacy Act (“GIPA”) may extend further than GINA.Footnote 134 The legislative intent of GIPA defines some familiar goals for the statute: the value of genetic testing to the individual and the public, and the failure of current statutory and regulatory structures to address public concerns regarding disclosure without proper consent.Footnote 135 While GIPA imposes a broader assumption of confidentiality than GINA, disclosure by the covered entity without consent of the individual is broadly permitted for public health activities, “to business associates” as defined in HIPAA,Footnote 136 and for general research purposes in accordance with HIPAA.Footnote 137 Privacy protections in the health setting have mainly relied on the safeguard of obtaining consent from the individual. However, the exclusions to consent in GIPA and HIPAA more broadly, particularly in light of the highly personal nature of genetic information, may not provide the assurances necessary to assuage the public's concern.
B. Development of Consent in the U.S.
With some exceptions, consent is now required in the United States for the collection and use of data from human subjects, but consent is not an ancient doctrine. In 1951, the individual who provided the HeLa cell line did so without informed consent, consistent with the law at the time.Footnote 138 By 1962, however, the United States passed the Kefauver-Harris amendments to the 1938 Food, Drug, and Cosmetic Act, which required researchers to notify participants if medications were being administered for investigational purposes and empowered the Food and Drug Administration to ban experiments pending safety determinations.Footnote 139 In 1966, a Surgeon General policy statement required any human subject research to undergo prior review.Footnote 140 The same year, the predecessor of DHHS published a regulation, summarized below, defining specific guidelines for informed consent.Footnote 141 In the 1980's the President's Commission for the Study of Ethical Problems in Medicine and Biomedical and Behavioral Research recommended that all federal agencies adopt the regulations suggested by HHS.Footnote 142 The main goal of obtaining consent is “to enable competent individuals to decide for themselves whether to participate in research,”Footnote 143 but with the aggregation of genomic data in biobanks, clinicians and researchers alike may face new challenges regarding the type of consent obtained and subsequent permitted uses.
Subpart A, more often referred to as the Federal Policy or the “Common Rule,” houses the current definitions, requirements, and exceptions applicable to informed consent for research involving human participants.Footnote 144 Under the Common Rule, informed consent requires using understandable language and facts that a reasonable person would want to know in order to make a decision about participation.Footnote 145 If the study involves collection of identifiable private information or biospecimens, then a statement must be provided “that identifiers might be removed from the identifiable private information or identifiable biospecimens and that, after such removal, the information or biospecimens could be used for future research studies or distributed to another investigator for future research studies without additional informed consent from the subject or the legally authorized representative, if this might be a possibility,”Footnote 146 or a statement that “the subject's information or biospecimens collected as part of the research, even if identifiers are removed, will not be used or distributed for future research studies.”Footnote 147 A specific statement must be included if the research will include whole genome sequencing.Footnote 148
Currently, the biobanking and genomic research communities are independently adopting consent structures that rely heavily on broad or open consent, challenging the traditional legal norms for informed consent.Footnote 149 It has been demonstrated that the traditional models of informed consent are inappropriate for genetic research and biobanking.Footnote 150 At the time of collection, it is impossible to describe or predict the future research uses for which that biospecimen and genetic data may be used.Footnote 151 Additionally, the repeated contact necessitated by an informed consent requiring further consent for subsequent uses would be prohibitively time consuming and costly for researchers, and probably dissuasive and confusing for participants.Footnote 152 Furthermore, because of the scientific complexity inherent in genetics research, simply satisfying the goal of “informing” the participant is challenging, as people may not even understand the mechanics or implications of what they are consenting to.Footnote 153
A new revision to the Common Rule, called the Final Rule,Footnote 154 permits broad consent as an alternative to informed consent, and identifies the requisite elements for obtaining broad consent for the storage, maintenance, and secondary research use of identifiable private information.Footnote 155 Here, the participant must be provided with a statement describing the types of research that might be conducted, a description of what identifiable private information may be used, and the period of time the information will be stored or maintained.Footnote 156 However, with broad consent participants are also informed that “they will not be provided of the details of any specific research studies that might be conducted using the … identifiable private information or identifiable biospecimens, including the purposes of the research, and that they might have chosen not to consent to some of those specific research studies.”Footnote 157 A general shift to broad consent may “reflect more the power of the research institutions' lobby than a conceptually and legally coherent policy change.”Footnote 158 Furthermore, with the emphasis on broad, international collaboration in biobanking and precision medicine, the effectiveness of consent principles are only as strong as the weakest link.
IV. CONSENT ABROAD
The challenges to obtaining adequate consent and ensuing privacy concerns are further complicated in light of the rise of global research networks, sequence referencing libraries, and international consortiums that rely on freely shared genomic data.Footnote 159 This connectivity greatly accelerates the pace of research and discovery, allowing scientists and researchers internationally to share results and avoid wasting resources, effectuating great benefit to the public.Footnote 160 International connectivity also tests the “traditional workhorses of medical research governance—informed consent, withdrawal, anonymization, and oversight mechanisms[.]”Footnote 161
In many countries, the oversight mechanisms in place for medical research are national oversight bodies, which do not individually have the authority, diplomatic weight, or expertise to assess the risks or ensure compliance in the face of global data sharing.Footnote 162 In response, there have been several attempts to reach international consensus on consent protocol.Footnote 163
Medical research models and general guidelines, however, are often predicated on altruistic motivations and inquest solidarity.Footnote 164 Whether national or international, guidelines shaped mainly by private interest or biopharma would likely cut against the rights of the individual regarding informed consent and data privacy. Additionally, a private resolution seems more likely in the wake of slow consensus among individual countries, as well as for international agreement.Footnote 165 Furthermore, regardless of how well-crafted international regulations and guidelines are, the possibility of bad actors or a hacking incidents looms.Footnote 166
V. CURRENT MODELS
The benefit of precision medicine and genomic research requires that data collection, research methodology, and technology development incentives, “extend beyond our borders, through collaborations with related projects around the world.”Footnote 167 The collaborative research foundation laid by the HGP is alive and well today.Footnote 168 However, to achieve widespread participation, and widespread public benefit, researchers need to gain public trust. Trust regarding genetic data is particularly tenuous when industryFootnote 169 and international sharingFootnote 170 are involved. The ethical and legal ambiguities regarding consent, ownership, storage, and use of genetic data have no regulatory consensus, neither in the U.S. nor abroad,Footnote 171 and public reticence to share genetic data in this climate could deter progress.Footnote 172
Despite these challenges, a few Nordic countries provide interesting models to consider for managing public concern over consent and privacy in biobanking and genetic research, while encouraging scientific progress in genetic health research.Footnote 173 Nordic countries have pioneered national biobanks, and in 2011, several Nordic countries banded together to create NordForsk, a common genetic database, under the Nordic Council of Ministers which provides funding for cooperative research projects and infrastructure.Footnote 174 Among the 2019-2022 goals for NordForsk is to “further promote open science and open access” while “requiring that research activities have appropriate systems for ensuring compliance with national and international ethical standards and commonly accepted professional codes and norms.”Footnote 175 Though seemingly broad, this goal identifies compliance with ethical standards as a prerequisite, not an assumption, of collaboration. This type of goal, in an international setting, may prevent sharing of genetic data with countries with weak enforcement of ethical standards.
Ultimately, NordForsk leaves the specifics of legislation and regulation for biobanks and genetic research up to individual nations.Footnote 176 In 2018, NordForsk published an overview on biotechnology legislation in Nordic countries that specifically identifies how each country handles consent.Footnote 177 Each country's approach to consent for biobanked data is different. Denmark's consent structure requires “anyone not wishing their cells or tissue used for anything other than the treatment and diagnosis of themselves may register in the Use of Tissue Registry,” and requires informed consent for samples taken specifically for research purposes.Footnote 178 Norway presumes consent for diagnostic and clinical purposes, but requires informed consent for scientific research.Footnote 179 Sweden requires informed consent, but defines it more broadly: “the donor must be informed of the intention and purpose or purposes of the biobank in question.”Footnote 180 Additionally, Sweden requires new informed consent for further use of samples, but that consent can be bypassed by a board of ethics if the data is being used for research or a clinical trial.Footnote 181
In 2013, Finland was one of the first nations to pass legislation specifically addressing biobanking.Footnote 182 The Biobank Act stabilizes biobanking activities, encourages horizontal collaboration, and creates a legal framework for all participants.Footnote 183 Similar to Sweden, Finland requires informed consent “based on adequate information about the biobank in question, nature of the biobank activities, risks, right to withdraw, etc.”Footnote 184 However, Finland's provision on the transfer of data into a biobank strikes a unique middle ground for managing public concern and the interests of the genetic research community. For the transfer of genetic data, Finland has an “opt-out” consent structure that also requires notice, whereby old clinical and research samples can be transferred subject to personal or public notice unless the individual opts out.Footnote 185 This has been called broad consent, but does not have the same “black box” connotations as most other provisions, because an individual preserves the right to object to downstream use.Footnote 186 With wide public support, Finland is launching FinnGen, “one of the very first personalized medicine projects at this scale, and the public-private collaborative nature of the project is exceptional compared to many ongoing studies.”Footnote 187 Biobanking and the further development of precision medicine is now part of Finland's long-term growth plan.Footnote 188
Estonia provides a uniquely coherent model for biobanking and precision medicine that is constructed around the Estonian Human Genes Research Act (“EHGRA”), a law that gives fundamental protection to gene donors' privacy.Footnote 189 EHGRA “establishes anonymity in clinical research, enables donors to decide which studies they want to participate in, and gives donors full control over who has access to their data.”Footnote 190 The portal through which donors can access their data is the same portal through which Estonians “pay their taxes, fill prescriptions, and open a business, among other things.”Footnote 191 Ain Aaviksoo, the former Chief Innovation and Digital Officer with Estonia's Ministry of Social Affairs, likens the e-Health portal to basic education, where the government has created a floor for medical access, voluntary and accessible to all residents.Footnote 192 Eric Lander, president and founding director of The Broad Institute at MIT and Harvard, has endorsed Estonia as a model for the future of genomic medicine.Footnote 193
VI. RECOMMENDATIONS
Humankind is riding on the crest of a massive wave towards greater efficiency and effectiveness with precision medicine. The Nordic countries provide interesting case studies for how to manage privacy and consent in biobanking and precision medicine initiatives, both as individual nations, and in the context of an international cooperative effort.Footnote 194 Estonia provides a model for participant-centered research, as well as a design for ongoing access to see how data are being used.Footnote 195 Denmark's opt-out structure allocates the burden of choice to the participant, giving participants decisional privacy over their data without being too impractical and onerous for researchers.Footnote 196 Both Finland and Denmark are structuring their precision medicine initiatives on public-private partnerships.Footnote 197
The main goal of obtaining consent is “to enable competent individuals to decide for themselves whether to participate in research.”Footnote 198 The achievement of that goal in the U.S. will likely look different from in Nordic countries. While none of the models perfectly address privacy concerns, in formulating its own approach to biobanking and privacy protection, the U.S. has the opportunity to take utilize tools of consent that have been demonstrated elsewhere.
The Precision Medicine Initiative published broad recommendations to maintain the participants' privacy and trust, as well as data security.Footnote 199 Broad goals to address privacy and trust include specific recommendations on governance, transparency, participant preference, and participant access.Footnote 200 The recommendations include creation of a dynamic and ongoing consent process, informing participants of when and how data are used, and allowing participants to withdraw consent at any point.Footnote 201 Though researchers and the Common Rule have embraced broad consent,Footnote 202 dynamic consent may more effectively assuage participants' privacy concerns regarding their genetic data.
Dynamic consent is a participant-centered approach, usually involving a web-based interface allowing interaction with the biobank custodians and researchers, providing real-time information about research, and allowing for continuous and easy opt-out mechanisms.Footnote 203 Dynamic consent is not as favorable for the research community as broad consent, particularly if the consent is retained by the biobank via opt-in, rather than opt-out, mechanisms.Footnote 204 Whether opt-in or opt-out, the conversation around obtaining meaningful consent for storage and use of genetic data is moving away from a static, single point in time acquisition.Footnote 205 Currently, the National Institutes of Health via the National Centers for Biomedical Computing is funding the iDASH initiative, which has identified several consent “dimensions includ[ing] (i) the characteristics of the institutions that can access the patient's data, (ii) the level of details that each institution can access, and (iii) the type of research allowed on the data (all possible uses of the data).”Footnote 206 A dynamic consent structure would give the participant the power to opt-out of data sharing internationally, and would also give them the power to later change that term of consent for intra-country only sharing if desired. The patient could specify that they want their data used only for cancer research, and later change their mind to include Alzheimer's disease. The importance of consent withdrawal and participant education regarding storage and usage of their genetic data will give participants some ongoing protection over their informational and decisional privacy. In the absence of anonymity, dynamic consent is only a meaningful change if the consent attaches to the genetic data, insuring downstream, secondary research uses adhere to the individual's requirements. Dynamic consent strikes a balance between participants' fear of the black box of broad consent and researchers' fear of unwieldy informed consent. While the best balance likely involves more than broad consent, researchers recognize that a “[l]ack of sufficient protection on sensitive human genome data can put individuals' privacy at risk,” and are working towards developing a workable solution.Footnote 207
Additionally, though a “single, binding, international instrument to govern privacy in genomic biobanking”Footnote 208 is unlikely to occur, NordForsk demonstrates that, among nations that agree on ethical standards, international research and precision medicine initiatives can thrive, and individuals in turn will benefit from biobanks sharing data, funding, strategy, and findings.Footnote 209 In May of 2018, as part of the Precision Medicine Initiative, the United States rolled out the All of Us Research Program.Footnote 210 While concentrated data necessarily incurs a higher risk of hacking and breach,Footnote 211 countries can also limit data sharing with partners that have similar data security and encryption policies as their own to ensure protection of participants' privacy on the back end. The best solutions to the public concern about genetic data consent and privacy will balance participant choice, efficient sharing, and good governance. While regulatory actors are moving slowly, individual research institutions and biobanks are enacting their own consent and privacy structures.Footnote 212 Rapid changes to medicine inspired by genomics are forcing a renewed conversation about consent. The old governance structures have not kept up with the new technology. New technology, however, does not necessitate a surrender of legal rights, but an adaptation of the governance structure.
